Notícias e Atividades da Anthos Therapeutics

Veja o organograma con seus 28 executivos principais

Biografias mais buscadas da Anthos Therapeutics

• Bill Meury, Chief Executive Officer
• Ari Brettman, Director
• Scott Beardsley, Director

Recentes movimentos de executivos em Anthos Therapeutics

• Venkat Ramanan, ingressou na Companhia como Chief Financial Officer  (Notícia publicada em 1 de novembro de 2024).
• Will Kane, ingressou na Companhia como President and Chief Commercial Officer  (Notícia publicada em 1 de novembro de 2024).
• Laurel Ostrom, ingressou na Companhia como Chief Human Resources Officer  (Notícia publicada em 11 de outubro de 2024).

Clique aqui para ver outras movimentos em Anthos Therapeutics

Criar um alerta
para seguir os movimentos de executivos da Anthos Therapeutics.

Anthos Therapeutics possui 2.351 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Genus (Reino Unido).

Popular M&A news in Biotecnologia

• Transcarent and Accolade have merged  (publicado em 9 de abril de 2025)..
• Kashiv BioSciences acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 7 de abril de 2025).
• Atsena Therapeutics acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 4 de abril de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Kristina Burow - Director da Scholar Rock
• Steven Gillis - Chairman of the Board da VBI Vaccines
• Ali Behbahani - Non-Executive Director da Adaptimmune Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Anthos Therapeutics

• Blackstone Life Sciences and Anthos Therapeutics Announce Novartis has Completed the Acquisition of Anthos Therapeutics in a Deal Valued at up to $3.1B, with $925M Paid Upfront - Anthos Therapeutics
• Anthos Therapeutics Shares New Data from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Significantly Reduced Bleeding in Patients Regardless of Age or Bleeding Risk - Anthos Therapeutics
• Anthos Therapeutics Shares New Data from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Significantly Reduced Bleeding in Patients Regardless of Age or Bleeding Risk - Anthos Therapeutics
• Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 billion  - Anthos Therapeutics
• Data Published Today in the New England Journal of Medicine Demonstrates Anthos Therapeutics’ novel Factor XI inhibitor, Abelacimab 150mg, Reduced Major or Clinically Relevant Non-Major Bleeding by 62% Compared to Rivaroxaban (Xarelto) in Patients with At
• Anthos Therapeutics Shares New Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Substantially Reduced Bleeding in Patients on Antiplatelet Therapy Compared to Rivaroxaban - Anthos Therapeutics
• Anthos Therapeutics Appoints Will Kane as President and Chief Commercial Officer and Venkat Ramanan as Chief Financial Officer - Anthos Therapeutics
• Anthos Therapeutics Appoints Mia Kelley as General Counsel and Laurel Ostrom as Chief Human Resources Officer - Anthos Therapeutics
• New anti-clotting medication reduces bleeding among people with atrial fibrillation
• New anti-clotting medication found to reduce bleeding among people with atrial fibrillation
• View more press releases Close

Redes sociais sobre Anthos Therapeutics

• Anthos Therapeutics na Wikipedia, Google News e Yahoo Finance
• Anthos Therapeutics na LinkedIn, Twitter e YouTube